BlackRock Institutional Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

BlackRock Institutional Trust’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$167K	Hold	11,195	–	–	﹤0.01%	3603
2016 Q3	$142K	Hold	11,195	–	–	﹤0.01%	3658
2016 Q2	$102K	Sell	11,195 -23,510	-68%	-$282K	﹤0.01%	3704
2016 Q1	$292K	Sell	34,705 -251	-0.7%	-$2.1K	﹤0.01%	3554
2015 Q4	$431K	Buy	34,956 +8,887	+34%	+$244K	﹤0.01%	3533
2015 Q3	$1.59M	Buy	26,069 +2,691	+12%	+$194K	﹤0.01%	3196
2015 Q2	$1.82M	Buy	23,378 +2,568	+12%	+$215K	﹤0.01%	3153
2015 Q1	$1.41M	Buy	20,810 +240	+1%	+$20.6K	﹤0.01%	3243
2014 Q4	$1.91M	Buy	20,570 +461	+2%	+$47.7K	﹤0.01%	3126
2014 Q3	$2.12M	Sell	20,109 -46	-0.2%	-$6.4K	﹤0.01%	3056
2014 Q2	$2.88M	Buy	20,155 +2,014	+11%	+$294K	﹤0.01%	3027
2014 Q1	$2.74M	Buy	18,141 +1,057	+6%	+$208K	﹤0.01%	3034
2013 Q4	$3.13M	Buy	17,084 +1,466	+9%	+$268K	﹤0.01%	2981
2013 Q3	$3.45M	Buy	15,618 +67	+0.4%	+$14.3K	﹤0.01%	2883
2013 Q2	$2.72M	Buy	+15,551	New	+$4.05M	﹤0.01%	2945

Other funds holding MDGL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

BlackRock Institutional Trust's MDGL Position: Q4 2016 in Review

BlackRock Institutional Trust held its Madrigal Pharmaceuticals (MDGL) position steady in Q4 2016 at 11,195 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #3603.

BlackRock Institutional Trust first reported a position in MDGL in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.45M in Q3 2013. 31 funds tracked by Wall St. Rank hold MDGL as of Q4 2016.

BlackRock Institutional Trust held 11,195 shares of Madrigal Pharmaceuticals worth $167K as of Q4 2016.
BlackRock Institutional Trust left its Madrigal Pharmaceuticals share count unchanged in Q4 2016.
Madrigal Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3603 holding.
BlackRock Institutional Trust first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Madrigal Pharmaceuticals position peaked at $3.45M in Q3 2013.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.